Brain imaging techniques could be the most effective way to measure the progression of Huntington Disease, according to a study published this month in The Lancet.
Currently, clinical trials involving Huntington Disease require lengthy observation periods of the genetic disorder that effects muscle control and cognitive behavior. But researchers at the University College London believe they have found a more effective way to enhance the development of drugs through MRI.
The longitudinal study, known as TRACK-HD, looked at subjects over a two-year period. Researchers believe it’s possible their findings may improve the efficiency of clinical trials. With these latest findings, sample size and trail duration could decrease, resulting in a more refined understanding of the disease.
For the study abstract click here.
For an in-depth article about the study at Medscape.com click here.